The SWI-SNF complex can not 'run the show' alone, however. In the absence of both the promoter and enhancer, targeting of Brg1 does not restore recombination. Enhancer activity, therefore, must do ...

As many as 1 in 4 cancers are driven by mutations in the SWI/SNF chromatin-remodeling complex, which controls access to DNA. A study led by St. Jude Children's Research Hospital recently identified ...

Scientists have determined how the SWI/SNF chromatin remodeling complex helps cancer cells 'remember' how to be cancerous after division. When a cell divides, it retains information about how to grow ...

The SWI/SNF protein complex was already known to carry out such changes, but it was unclear whether each of the three variants did so in a unique way or led to distinct macrophage behavior. To learn ...

Precision and timing of gene expression is essential for normal biological functions and, when disrupted, can lead to many human diseases, including cancers. However, how molecular machines—protein ...

Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1). This is an ASCO Meeting Abstract from the 2022 ASCO ...

A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States.

Most lung adenocarcinoma tumors with EGFR mutations respond to tyrosine kinase inhibitors (TKIs, e.g., osimertinib). Accordingly, there are now >50 different FDA-approved TKIs. Still, acquired ...

Scientists at St. Jude Children’s Research Hospital found that subunits of the SWI/SNF chromatin remodeling complex, which is mutated in 20% of all cancers, help cells maintain a memory of ...